

Engagement Report for Clinical Commissioning Policy Statements

Unique Reference Number	1781
Algorithm Title	Disease modifying therapies for multiple sclerosis.
Lead Commissioner	Jacque Kemp
Clinical Reference Group	Neurosciences
Which stakeholders were contacted to be involved in policy development?	Full registered Neuro CRG stakeholder list plus Multiple sclerosis society Multiple sclerosis UK MS clinicians and neurologists
Identify the relevant Royal College or Professional Society to the policy and indicate how they have been involved	Nursing – neurological nursing association (NNA) Association of British Neurologists (ABN) ABN on working group and engaged in further request for feedback
Which stakeholders have actually been involved?	ABN NNA MS society MS UK Neurology consultants National CRG neuro lead for MS NHS England pharmacy Bluteq
Explain reason if there is any	Working group was expanded to include wide ranging engagement from specialists with an interest in MS and pharmacy leads.

difference from previous question	
Identify any particular stakeholder organisations that may be key to the policy development that you have approached that have yet to be engaged. Indicate why?	<p>MS society was active and engaged members of the working group.</p> <p>MS Society involved in circulating for opinion</p> <p>Generically has support from organisations including MS society and ABN</p> <p>This was circulated to the ABN and endorsed</p> <p>It was also discussed with clinical leads across the country to collect views</p>
How have stakeholders been involved? What engagement methods have been used?	<p>Circulation as a draft document.</p> <p>Membership on working group.</p> <p>ABN working group have reviewed and endorsed</p> <p>Vote taken amongst clinicians to achieve consensus on MDTs</p>
What has happened or changed as a result of their input?	<p>Shared as an improving value scheme</p> <p>Blueteq reporting in place for all of the pathway and updated as required</p> <p>Extensive circulation to clinical colleagues for input</p> <p>Wording about MDT requirement enforced after consultation with clinical leaders</p>
How are stakeholders being kept informed of progress with policy development as a result of their input?	<p>Updated via working group and charities meetings every 6 months</p> <p>enthusiasm for this to be adopted</p> <p>Improving value- available on Sharepoint</p> <p>Some regions have adopted this as an improving value scheme</p> <p>Update to extended clinical forum and charities as to progress of algorithm</p>
What level of wider public consultation is recommended by the CRG for the NPOC Board to agree as a result of stakeholder involvement?	<p>The CRG have had regular updates on the development of the algorithm and it has been circulated to regions as part of the improving value scheme.</p> <p>On the 5th December the PoC Board endorsed and supported the algorithm and supporting documents to go to clinical panel for approval to go out to public consultation for two months.</p> <p>The POC Board acknowledged that the algorithm had been in use as part of the IV scheme and as such had been shared widely with regions and providers and questioned whether any further</p>

	consultation was required. Decision to consult further as not all regions and providers have accessed this previously.
--	--

Draft for public consultation